Pay in 4 interest-free payments of $5.53 Learn more
Ships within 48 hours · Estimated delivery Oct 9 - Oct 14
Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease
doi: 10.1007/s00134-011-2293-2 213 CheeRAgahRVitaRBenvengaS
These concerns often overlap
As a physician-scientist, he applies his expertise in molecular pathology, biology, genomics, and technology development to advance treatments for patients
PMID: 40191829 Mol Biol Rep Targeting UBE2B-mediated U2AF1 degradation to alleviate endothelial dysfunction in renal ischemia-reperfusion injury: therapeutic potential of semaglutide
US$ 24.68
US$ 20.34
US$ 22.60
US$ 20.22
US$ 20.22
US$ 29.58
US$ 27.04
